Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Sinopharm COVID-19 Vaccine is 79% Effective in Phase III Trial
A Sinopharm COVID-19 vaccine with an inactivated virus mechanism was 79% effective in a Phase III test, which was conducted outside of
Sinopharm has submitted data to
"The protective effect of the (Sinopharm CNBG Beijing) vaccine against Covid-19 is 79.34%," said the Beijing Institute of Biological Products, a Sinopharm subsidiary.
Earlier this month, the
Outside observers are frustrated that
In
"China has made the firm commitment that after China's new coronavirus vaccines are completed and put into use, they will serve as a global public product and be supplied to the world at a fair and reasonable price," foreign ministry spokesman Zhao Lijian said Friday. "We will also give priority to developing countries for vaccines. This will be made through a variety of ways, including through donations and aid."
See our other articles on Sinopharm.
Disclosure: none.
Upcoming Events
BIO-Europe®
Register here
Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Other Relevant Events
Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here